特此通告。 黑龙江省药品监督管理局 2025年7月2日 黑龙江省药品监督管理局药品GMP符合性检查结果通告（2025年 第6号） 按照《药品管理法》及《国家药监局关于实施新修订<药品生产监督管理办法>有关事项的公告》（2020年第47号）要求，经现场检查哈尔滨三联药业股份 有限公司等16家企业符合《药品生产质量管理规范（2010年修订）》要求。 药品GMP符合性检查企业目录（2025年 第6号） | 序 | 符合性 | 企业名 | | | 现场 | | | --- | --- | --- | --- | --- | --- | --- | | 号 | 检查编 | 称 | 检查范围 | 生产地址 | 检查 | 备注 | | | 号 | | | | 时间 | | | 1 | 黑药符 | 哈尔滨 三联药 | 311车间小容量注射剂生产线:小容量注射剂（非最终灭菌） （抗肿瘤药） | | 2025 年4月 | | | | 查 | 业股份 | | 哈尔滨市利民开发区北京路 | 26日 | | | | 2025034 | 有限公 | | | —4月 | | | | | 司 | | | 29日 | | | 2 | 查 | ...

Group 1 - The article emphasizes the ongoing battle against drug trafficking, highlighting the dangers faced by law enforcement in this field, particularly in the Yunnan province of China [1][3][33] - The geographical location of cities like Mangshi and Ruili in Yunnan makes them critical areas in the fight against drug trafficking [3] - The article details specific drug busts, including the seizure of over 30 kilograms of drugs, including heroin and methamphetamine, during a routine vehicle inspection [7][13] Group 2 - The article recounts the story of police officer Yin Mingzhi, who sacrificed his life during a drug bust, illustrating the personal risks taken by law enforcement [15][19] - It describes the ongoing efforts of the Yunnan Dehong Border Management Team, which has successfully disrupted drug trafficking operations, including the interception of suspicious packages [24][33] - The article notes that from early 2025 to mid-June, the Dehong Border Management Team has solved 54 drug cases, arrested 56 suspects, and seized over 409 kilograms of various drugs [33]

Core Viewpoint - The Chinese judiciary is intensifying efforts to combat drug-related crimes, particularly focusing on severe penalties for drug offenses and special protections for minors, as evidenced by recent case announcements and statistical data [1][2][4]. Group 1: Drug Crime Statistics - In 2024, Chinese courts concluded 35,859 drug crime cases, with a 29.31% year-on-year decrease in the first five months of 2025, indicating a positive trend in drug crime governance [1][2]. - The overall decline in drug crime cases over the past decade reflects the effectiveness of China's drug control measures [1]. Group 2: Severe Punishments for Drug Crimes - The judiciary maintains a strict stance against severe drug crimes, as demonstrated by the death penalty for individuals like Su Mouhe and Wen Mouhong, who engaged in large-scale drug trafficking and violent resistance against law enforcement [3][4]. - The courts emphasize a "quantity + other circumstances" standard for sentencing, ensuring that punishments are commensurate with the severity of the crime [4]. Group 3: New Drug Crime Trends - New types of drug crimes are on the rise, with offenders utilizing advanced technology, the internet, and virtual currencies to facilitate drug trafficking, as seen in cases involving LSD and "smart drugs" [6][8][9]. - The emergence of new drugs disguised as everyday products poses significant risks, particularly to youth, highlighting the need for ongoing vigilance and education [10][12]. Group 4: Protection of Minors - The judiciary is particularly focused on protecting minors from drug-related crimes, with cases involving the sale of drugs disguised as harmless products, such as "head-up e-cigarettes" and cough syrups, being prosecuted vigorously [10][11][12]. - The courts are taking a firm stance against individuals who target minors for drug sales, reflecting a commitment to safeguarding youth from the dangers of drug abuse [12][13].

仙乐健康科技股份有限公司相关 债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【157】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客 观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经授 ...

2025年6月23日，重庆市第一中级人民法院公开宣判李静波特大毒品犯罪案，以走私、贩卖、运输毒品 罪、洗钱罪、偷越国（边）境罪、故意伤害罪数罪并罚， 判处被告人李静波死刑，剥夺政治权利终身， 并处没收个人全部财产；以洗钱罪判处被告人王九江有期徒刑八年，并处罚金人民币200万元。 经审理查明：被告人李静波于2020年偷渡至境外，从境外组织毒品运往国内，或从国内其他省市组织毒 品，贩卖给其下家，或安排在国内的"马仔"接收后贩卖。从2020年6月至2023年11月，李静波多次走 私、贩卖、运输毒品海洛因、甲基苯丙胺（冰毒）、甲基苯丙胺片剂（俗称"麻古"）共计1.06余吨，运 输混有毒品甲基苯丙胺的茶叶1.07余吨，数量特别巨大；为掩饰毒品犯罪所得的来源及性质，李静波通 过被告人王九江将其毒品犯罪所得以"虚拟资产"交易方式进行转移，多次累计转移资金人民币4800余 万元，情节严重；违反国（边）境管理法规，偷越国（边）境，情节严重；在看守所羁押期间故意伤害 他人致一人轻伤二级。 重庆市第一中级人民法院认为，被告人李静波的行为构成走私、贩卖、运输毒品罪、洗钱罪、偷越国 （边）境罪、故意伤害罪，且系累犯、毒品再犯，依法从重 ...

Core Viewpoint - The Supreme People's Court highlighted the increasing issue of the abuse of narcotic and psychotropic drugs, particularly the illegal diversion of medical drugs into the drug market, as exemplified by the case of a hospital director involved in the illegal sale of a controlled substance [1][2][3] Group 1: Case Details - The defendant, Su, served as the director of a public hospital and exploited his position to illegally acquire and sell 536,180 tablets of a narcotic drug, with profits exceeding 1 million yuan [1][2] - Su sold approximately 380,000 tablets at prices ranging from 1.5 to 7 yuan each, primarily to unemployed individuals, facilitating the drug's entry into the illegal market [1][2] - The court found Su's actions constituted drug trafficking, given his awareness of the potential for abuse and the significant social harm caused by his actions [2][3] Group 2: Legal Consequences - Su was sentenced to death with a two-year reprieve, stripped of political rights for life, and ordered to forfeit all personal property due to the severity of his crimes [2][3] - The case underscores the serious legal repercussions for individuals in positions of authority who engage in illegal drug distribution, particularly in the context of increasing government crackdowns on drug-related crimes [2][3] Group 3: Industry Implications - The case reflects a broader trend where traditional drugs are becoming harder to obtain, leading some drug users to seek out medical narcotics as substitutes, raising concerns about the integrity of the healthcare system [2][3] - The dual nature of substances like fentanyl, which can be both a medication and a drug, poses significant risks to public health when diverted into illegal markets [3]

Group 1 - The Supreme People's Court emphasizes a consistent stance on severely punishing serious drug crimes, with notable cases including the death penalty for repeat offenders and those exploiting their positions for drug trafficking [1][2] - There is a clear attitude towards legally punishing new types of drug crimes, with 7 new drug cases highlighted, the highest proportion in history, aimed at raising public awareness about new drug threats [1][2] - The court strengthens judicial protection for minors, with severe penalties for those who involve minors in drug-related activities, demonstrating a commitment to safeguarding the health and growth of young people [2] Group 2 - The importance of comprehensive drug control measures is underscored, as it is seen as a fundamental strategy to eradicate drug crimes, with judicial recommendations aimed at addressing systemic issues in medical institutions [2]

Core Insights - ALK presented significant advancements in anaphylaxis and pediatric allergy at the EAACI 2025 congress, highlighting innovations in treatment options and clinical evidence [1][4] Group 1: Innovations in Anaphylaxis Treatment - The EURneffy nasal adrenaline spray was introduced as a new treatment for anaphylaxis, supported by real-world data demonstrating its effectiveness in acute cases [2] - The nasal spray's pharmacological response is comparable to that of intramuscular adrenaline injections in patients with allergic rhinitis [2] Group 2: Immunotherapy Developments for Children - ALK showcased clinical evidence for sublingual allergy immunotherapy tablets aimed at children with respiratory allergies, indicating a transformative potential for allergy care [3] - Real-life data supports the long-term benefits of allergy immunotherapy in managing both upper and lower airway diseases in children [3] - Preliminary findings from the ALLIANCE clinical trial suggest that the peanut SLIT-tablet may be a well-tolerated treatment option for children with peanut allergies [3]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 2025 年 6 月 10 日，浙江大学药学院 顾臻 教授 、浙江大学化学系 刘昭明 研究员 、 唐睿康 教授等，在 Nature Cancer 期刊发表了题为： Long-acting IL-2 release from pressure-fused biomineral tablets promotes antitumor immune response 的研究论文。 该研究开发了一种 压力融合的生物矿化片剂，实现 IL-2 的长效缓释，以促进抗肿瘤免疫反应。 长效控释药物制剂备受青睐，因其能增强药效并减少给药次数。在这项最新研究中，研究团队展示了一种通过 碳酸钙 （CaC） 和磷酸钙 （CaP） 无定形相的融 合及边界消除实现的可动态控制的长效白细胞介素-2 （IL-2） 释放平台。 并非简单的直接将 碳酸钙 （CaC） 和磷酸钙 （CaP） 进行混合，研究团队在 高压 （2 GPa） 条件制备了一组化学式为 Ca(CO 3 ) x (PO 4 ) 2(1− x )/3 （CaCP，0 < x < 1） 的杂化生物矿化物，其表现出结晶驱动的释放行为，以优化体内 I ...

百济神州美股涨近7%，FDA官网显示，百济神州的泽布替尼片剂获批上市。 ...